Pancreatic ductal adenocarcinoma (PDAC) is a malignancy characterized by a poor
prognosis and high mortality rate. Genetic mutations and altered molecular pathways serve …

Highlights•NRG1 fusions result in ErbB-mediated pathway activation and present a rational
therapeutic target.•ErbB-targeted treatments, such as afatinib, can be effective therapeutic …

Background Recent advances are enabling delivery of precision genomic medicine to
cancer clinics. While the majority of approaches profile panels of selected genes or hotspot …

We used whole-genome and transcriptome sequencing to identify clinically actionable
genomic alterations in young adults with pancreatic ductal adenocarcinoma (PDAC) …

Purpose: NRG1 gene fusions are rare but potentially actionable oncogenic drivers that are
present in some solid tumors. Details regarding the incidence of these gene rearrangements …

Purpose: Identification of clinically actionable molecular subtypes of pancreatic ductal
adenocarcinoma (PDAC) is key to improving patient outcome. Intertumoral metabolic …

Purpose: Gene fusions involving neuregulin 1 (NRG1) have been noted in multiple cancer
types and have potential therapeutic implications. Although varying results have been …

NRG1 rearrangements are oncogenic drivers that are enriched in invasive mucinous
adenocarcinomas (IMA) of the lung. The oncoprotein binds ERBB3–ERBB2 heterodimers …

Purpose: Immune checkpoint inhibitors (ICI) have revolutionized the treatment of solid
tumors with dramatic and durable responses seen across multiple tumor types. However …

With advances in tumour biology and immunology that continue to refine our understanding
of cancer, therapies are now being developed to treat cancers on the basis of specific …